Research programme: Immunological disorder therapeutics - Karma Biotechnologies
Alternative Names: Xavines™Latest Information Update: 16 Mar 2022
At a glance
- Originator Karma Biotechnologies
- Class Antiallergics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Autoimmune disorders; Food hypersensitivity; Hypersensitivity
Most Recent Events
- 01 Mar 2022 Early research in Food hypersensitivity in USA (unspecified route) (Karma Biotechnologies website, February 2022)
- 01 Mar 2022 Early research in Hypersensitivity in USA (unspecified route) (Karma Biotechnologies website, February 2022)
- 25 Feb 2022 Early research in Autoimmune disorders in USA (Parenteral) (Karma Biotechnologies website, February 2022)